GenSight Biologics
About
What does GenSight Biologics do?
GenSight Biologics is a biotechnology company advancing gene therapy for neurodegenerative ophthalmic diseases. They are developing treatments for conditions like Leber Hereditary Optic Neuropathy (LHON), Retinitis Pigmentosa (RP), and Geographic Atrophy in Dry-AMD, utilizing technologies such as gene therapy, mitochondrial targeting sequences, and optogenetics. Their clinical development includes GS010 (lenadogene nolparvovec) and GS030.
What is GenSight Biologics's revenue?
StartupHub estimates GenSight Biologics's annual revenue at $65.9M (range $36.1M to $170.5M, 44% confidence), based on comparable companies in the sector.
What is GenSight Biologics's valuation?
StartupHub estimates GenSight Biologics's effective valuation at $3.3M (range $1.3M to $6.4M, 56% confidence), based on comparable companies in the sector.
How much funding has GenSight Biologics raised?
GenSight Biologics has raised a total of $5M in funding. The most recent round on record is Unknown.
Where is GenSight Biologics headquartered?
GenSight Biologics is headquartered in Paris, France.
When was GenSight Biologics founded?
GenSight Biologics was founded in 2012.
What industry does GenSight Biologics operate in?
GenSight Biologics operates in Biotechnology, Healthcare, Gene Therapy, Ophthalmology.
No comments yet. Be the first to share your take.